Citation Impact
Citing Papers
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study
2009 StandoutNobel
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
2006
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
2006
Antithrombotic Therapy for Venous Thromboembolic Disease
2008 Standout
Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation
2005
Newer Pharmacotherapy in Patients Undergoing Percutaneous Coronary Interventions: A Guide for Pharmacists and Other Health Care Professionals
2006
Platelet pharmacogenomics
2010
Oxidative stress, aging, and diseases
2018 Standout
Evaluation of aspirin metabolites as inhibitors of hypoxia-inducible factor hydroxylases
2008 StandoutNobel
Clopidogrel with or without Omeprazole in Coronary Artery Disease
2010 Standout
High Residual Platelet Reactivity After Clopidogrel Loading and Long-term Cardiovascular Events Among Patients With Acute Coronary Syndromes Undergoing PCI
2011
Genetic polymorphisms of the platelet receptors P2Y12, P2Y1 and GP IIIa and response to aspirin and clopidogrel
2006
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
2013 Standout
INHIBITION OF ADP‐INDUCED PLATELET AGGREGATION BY CLOPIDOGREL IS RELATED TOCYP2C19GENETIC POLYMORPHISMS
2008
Platelet Reactivity After Clopidogrel Treatment Assessed With Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis
2009
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
2007
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
2009
PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy
2005
INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450
2006
No effects of atorvastatin (10mg/d or 80mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study
2015
Variability in Individual Responsiveness to Clopidogrel
2007
New Antithrombotic Drugs
2008
Pathology of Drug-Eluting Stents in Humans
2006 Standout
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
2008 Standout
Perioperative Management of Antithrombotic Therapy
2012 Standout
Pharmacogenetic Testing for Clopidogrel Using the Rapid INFINITI Analyzer
2009
Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent Thrombosis
2009
Antiplatelet Agents Aspirin and Clopidogrel Are Hydrolyzed by Distinct Carboxylesterases, and Clopidogrel Is Transesterificated in the Presence of Ethyl Alcohol
2006
Oral Anticoagulant Therapy
2012 Standout
Stent Thrombosis
2010
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
2007
Relation of Genetic Polymorphisms in the Cytochrome P450 Gene With Clopidogrel Resistance After Drug-Eluting Stent Implantation in Koreans
2009
Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy
2016
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
2009
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 Standout
Impact of P-glycoprotein on clopidogrel absorption
2006
Influence of the paraoxonase‐1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta‐analysis
2012
Antiplatelet Drugs
2011
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial
2007
Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease
2005
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
2009 Standout
Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients
2007
Increased Plasma and Platelet to Red Blood Cell Ratios Improves Outcome in 466 Massively Transfused Civilian Trauma Patients
2008 Standout
Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty
2009
Combining Antiplatelet and Anticoagulant Therapies
2009
Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention
2009 Standout
The Toll-like receptor 2/1 (TLR2/1) complex initiates human platelet activation via the src/Syk/LAT/PLCγ2 signalling cascade
2013 StandoutNobel
Durability of platelet inhibition by clopidogrel
2003
Role of Prasugrel, a Novel P2Y12 Receptor Antagonist, in the Management of Acute Coronary Syndromes
2009
Platelet Activation and Atherothrombosis
2007 Standout
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
2008
Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack
2013 Standout
Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel
2006
Pharmacology of Antiplatelet Agents
2013
Determinants of the interindividual variability in response to antiplatelet drugs
2005
The Effect of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Clopidogrel: A Possible Mechanism for Clopidogrel Resistance
2008
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
2021 Standout
Antiplatelet Drugs
2008
Lack of Evidence of a Clopidogrel–Statin Interaction in the CHARISMA Trial
2007
Findings of intravascular ultrasound during acute stent thrombosis
2004
Early Platelet Dysfunction: An Unrecognized Role in the Acute Coagulopathy of Trauma
2012
Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4
2009
The Year in Non–ST-Segment Elevation Acute Coronary Syndrome
2010
Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents
2008
The paraoxonase‐1 pathway is not a major bioactivation pathway of clopidogrelin vitro
2012
Prevention of Venous Thromboembolism
2004 Standout
Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently
2007
Clopidogrel–Drug Interactions
2011
Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis
2007
Impact of Genetic Polymorphisms and Drug – Drug Interactions on Clopidogrel and Prasugrel Response Variability
2010
Guidelines for Percutaneous Coronary Interventions
2005
Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system
2017
Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: Analytical and biological challenges
2016 Standout
Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin
2008 Standout
The Metabolism of Clopidogrel Is Catalyzed by Human Cytochrome P450 3A and Is Inhibited by Atorvastatin
2003
The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition
2016 Standout
Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome
2008
The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention
2010
Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel
2008
Prevention of Venous Thromboembolism
2008 Standout
Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis
2010
Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation
2006
Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome
2009
Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents
2006
Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects
2008
Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention
2008
Current Options in Platelet Function Testing
2006
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study
2013
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
2001 Standout
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis
2011
Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention
2011
Pre-Procedural Platelet Reactivity After Clopidogrel Loading in Korean Patients Undergoing Scheduled Percutaneous Coronary Intervention
2010
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
2011 Standout
Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine
2004
Thromboelastography in Orthopaedic Trauma Acute Pelvic Fracture Resuscitation
2016
Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis
2007
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting
2011
High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials
2012
P2 receptors, platelet function and pharmacological implications
2008
Guidelines for the use of fresh‐frozen plasma, cryoprecipitate and cryosupernatant
2004
Pilot Study of the Antiplatelet Effect of Increased Clopidogrel Maintenance Dosing and Its Relationship to CYP2C19 Genotype in Patients With High On-Treatment Reactivity
2010
Role of Reticulated Platelets and Platelet Size Heterogeneity on Platelet Activity After Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Patients With Stable Coronary Artery Disease
2008
Platelet-Active Drugs
2001
Admission Rapid Thrombelastography Can Replace Conventional Coagulation Tests in the Emergency Department
2012
The Pharmacogenetics and Pharmacodynamics of Clopidogrel Response
2008
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
2004
Measuring antiplatelet drug effects in the laboratory
2007
Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response
2012
Central role of the P2Y12 receptor in platelet activation
2004
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
2007 Standout
Platelet PAR1 receptor density—Correlation to platelet activation response and changes in exposure after platelet activation
2007 StandoutNobel
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
2006 Standout
International Consensus Recommendations on the Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding
2010 Standout
Patterned Hydrogels for Controlled Platelet Adhesion from Whole Blood and Plasma
2010 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents
2005 Standout
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
2008
Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel
2006
Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction
2004
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel
2009
Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies
2010
Cytochromes P450 Catalyze Both Steps of the Major Pathway of Clopidogrel Bioactivation, whereas Paraoxonase Catalyzes the Formation of a Minor Thiol Metabolite Isomer
2011
Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention
2005
Platelet Function Measurement–Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery
2012
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease
2009
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
2019 Standout
Clopidogrel Pharmacogenomics and Risk of Inadequate Platelet Inhibition: US FDA Recommendations
2009
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Drug Therapy in the Heart Transplant Recipient
2005
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation
2010
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2
2002 StandoutScience
Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention
2005
Clinical End Points in Coronary Stent Trials
2007 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Intraprocedural Stent Thrombosis During Implantation of Sirolimus-Eluting Stents
2004
Update on rifampin, rifabutin, and rifapentine drug interactions
2012
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose
2008
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack
2010 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Mechanism of Oxidation Reactions Catalyzed by Cytochrome P450 Enzymes
2004 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Monitoring of Clopidogrel Action: Comparison of Methods
2005
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
2009
Clopidogrel Response Variability and Future Therapies
2006
CYP2C19 and Nongenetic Factors Predict Poor Responsiveness to Clopidogrel Loading dose after Coronary Stent Implantation
2008
Works of Kirk E. Guyer being referenced
Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer.
1998
Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin
2014
Platelet Reactivity in Patients and Recurrent Events Post-Stenting
2005
Use of ICHOR‐platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors
2001
Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation
2003
Blood component therapy in trauma guided with the utilization of the perfusionist and thromboelastography.
2011
Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance
2004
Blood Component Therapy in Trauma Guided with the Utilization of the Perfusionist and Thromboelastography
2011